Trial Outcomes & Findings for SNAP VS BIS(OAA/S) Scale During a Sedation Regimen With and Without Ketamine (NCT NCT01250418)

NCT ID: NCT01250418

Last Updated: 2014-08-28

Results Overview

% Time Tosca Monitor (TcCO2) above 50. A TcCo2 above 50 is indicative of hypoventilation.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

25 participants

Primary outcome timeframe

Intraoperative, an average of about 1 and 1/2 hours.

Results posted on

2014-08-28

Participant Flow

Participant milestones

Participant milestones
Measure
Ketamine Group
ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
No Ketamine
No ketamine added to anesthesia regimen
Overall Study
STARTED
9
16
Overall Study
COMPLETED
8
15
Overall Study
NOT COMPLETED
1
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Ketamine Group
ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
No Ketamine
No ketamine added to anesthesia regimen
Overall Study
monitor data failure
1
1

Baseline Characteristics

SNAP VS BIS(OAA/S) Scale During a Sedation Regimen With and Without Ketamine

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Ketamine Group
n=9 Participants
ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min. Ketamine group: ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
No Ketamine
n=16 Participants
No ketamine added to anesthesia regimen
Total
n=25 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Age, Categorical
Between 18 and 65 years
9 Participants
n=39 Participants
16 Participants
n=41 Participants
25 Participants
n=35 Participants
Age, Categorical
>=65 years
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Sex: Female, Male
Female
9 Participants
n=39 Participants
16 Participants
n=41 Participants
25 Participants
n=35 Participants
Sex: Female, Male
Male
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Asian
0 Participants
n=39 Participants
1 Participants
n=41 Participants
1 Participants
n=35 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=39 Participants
4 Participants
n=41 Participants
5 Participants
n=35 Participants
Race (NIH/OMB)
White
8 Participants
n=39 Participants
11 Participants
n=41 Participants
19 Participants
n=35 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Region of Enrollment
United States
9 participants
n=39 Participants
16 participants
n=41 Participants
25 participants
n=35 Participants

PRIMARY outcome

Timeframe: Intraoperative, an average of about 1 and 1/2 hours.

% Time Tosca Monitor (TcCO2) above 50. A TcCo2 above 50 is indicative of hypoventilation.

Outcome measures

Outcome measures
Measure
Ketamine Group
n=8 Participants
ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min. Ketamine group: ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
No Ketamine
n=15 Participants
No ketamine added to anesthesia regimen
TcCO2 Above 50
39 Percent time intraoperatrive
Standard Deviation 26.54
30.8 Percent time intraoperatrive
Standard Deviation 26.14

Adverse Events

No Ketamine Added to Anesthesia Regimen

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Ketamine Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Gildasio De Oliveira MD

Northwestern University

Phone: 312-472-3573

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place